Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas

Area of Science:

• Oncology
• Medical Genetics

Background:

• Adult soft tissue sarcomas (STS) comprise a rare and heterogeneous group of cancers, necessitating subtype-specific treatment strategies.
• Traditional cytotoxic chemotherapies like doxorubicin and ifosfamide are standard, but emerging evidence supports subtype-specific agents.

Framework:

• Chemotherapeutic efficacy varies by STS subtype, with gemcitabine in leiomyosarcomas, trabectedin in leiomyosarcomas and liposarcomas, and taxanes/gemcitabine in angiosarcoma.
• Targeted therapies demonstrate significant activity, including imatinib for dermatofibrosarcoma and mammalian target of rapamycin (mTOR) inhibitors for perivascular epithelioid cell tumors (PEComas).

Implementation:

• Specific targeted agents show promise: crizotinib for ALK-rearranged inflammatory myofibroblastic tumors.
• Pazopanib exhibits activity in leiomyosarcoma and synovial sarcoma, while sunitinib, cediranib, sorafenib, and bevacizumab-temozolomide show potential in other STS subtypes.
• Pazopanib has also demonstrated prolonged progression-free survival in pre-treated advanced STS patients (excluding liposarcomas).

Implications:

• The growing number of effective subtype-specific treatments underscores the need for novel clinical trial designs for rare cancers.
• Balancing anecdotal evidence of highly specific treatments with statistically robust data from broader trials is crucial for advancing STS care.
• Personalized medicine approaches are transforming the management of adult soft tissue sarcomas, improving outcomes through tailored therapeutic strategies.